Royal Perth Hospital, Perth, Western Australia, Australia.
Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
PLoS One. 2023 Apr 11;18(4):e0283394. doi: 10.1371/journal.pone.0283394. eCollection 2023.
Inclusion body myositis (IBM) is the most commonly acquired skeletal muscle disease of older adults involving both autoimmune attack and muscle degeneration. As exercise training can improve outcomes in IBM, this study assessed whether a combination of testosterone supplementation and exercise training would improve muscle strength, physical function and quality of life in men affected by IBM, more than exercise alone.
This pilot study was a single site randomised, double-blind, placebo-controlled, crossover study. Testosterone (exercise and testosterone cream) and placebo (exercise and placebo cream) were each delivered for 12 weeks, with a two-week wash-out between the two periods. The primary outcome measure was improvement in quadriceps isokinetic muscle strength. Secondary outcomes included assessment of isokinetic peak flexion force, walk capacity and patient reported outcomes, and other tests, comparing results between the placebo and testosterone arms. A 12-month Open Label Extension (OLE) was offered using the same outcome measures collected at 6 and 12-months.
14 men completed the trial. There were no significant improvements in quadriceps extension strength or lean body mass, nor any of the secondary outcomes. Improvement in the RAND Short Form 36 patient reported outcome questionnaire 'emotional wellbeing' sub-category was reported during the testosterone arm compared to the placebo arm (mean difference [95% CI]: 6.0 points, [95% CI 1.7,10.3]). The OLE demonstrated relative disease stability over the 12-month period but with a higher number of testosterone-related adverse events.
Adding testosterone supplementation to exercise training did not significantly improve muscle strength or physical function over a 12-week intervention period, compared to exercise alone. However, the combination improved emotional well-being over this period, and relative stabilisation of disease was found during the 12-month OLE. A longer duration trial involving a larger group of participants is warranted.
包涵体肌炎(IBM)是最常见的获得性老年成人大骨骼肌疾病,涉及自身免疫攻击和肌肉退化。由于运动训练可以改善 IBM 的预后,因此本研究评估了在 IBM 男性患者中,与单独运动训练相比,睾酮补充和运动训练的联合应用是否会改善肌肉力量、身体机能和生活质量。
这是一项单中心、随机、双盲、安慰剂对照、交叉研究。睾酮(运动和睾酮乳膏)和安慰剂(运动和安慰剂乳膏)分别给药 12 周,两个治疗期之间有两周的洗脱期。主要结局测量是股四头肌等速肌力的改善。次要结局包括等速峰值屈膝力、步行能力和患者报告的结果以及其他测试的评估,比较安慰剂和睾酮组之间的结果。提供了为期 12 个月的开放标签扩展(OLE),使用相同的结局测量在 6 个月和 12 个月时收集。
14 名男性完成了试验。股四头肌伸展力量或瘦体重均无显著改善,也没有任何次要结局改善。与安慰剂组相比,睾酮组在 RAND 简明健康调查问卷“情感健康”亚量表中报告了改善(平均差异[95%CI]:6.0 分,[95%CI 1.7,10.3])。OLE 显示在 12 个月期间疾病相对稳定,但与睾酮相关的不良事件数量更多。
与单独运动训练相比,在 12 周干预期间,添加睾酮补充剂并未显著改善肌肉力量或身体机能。然而,在这段时间内,联合治疗改善了情感健康,在 12 个月的 OLE 期间发现了疾病的相对稳定。需要进行更长时间的试验,涉及更多的参与者。